Medicane R&D | News

Medicane R&D | From the Press

The Center for Cannabis Medicine, in cooperation with a global giant, will introduce 12 marijuana-based prescription products to pharmacies

The Hemp Medicine Center Group (CMK) – a leader on the Polish market of medical services using medical marijuana therapy, is scheduled to introduce hemp products to pharmacies in 2024, offered by the German pharmaceutical giant Sanity Group. After the registration process, CMK will be the only entity with such a diverse portfolio of medical marijuana products in the country. The medicinal marijuana industry is gaining importance, and more and more people are using cannabis plant therapy. Despite this, Polish patients struggle with, among others: with the lack of availability of dried herb or a limited selection of preparations and medicines based on hemp. In 2023, the Center for Hemp Medicine established cooperation with Sanity Group (a company from the Vayamed family, which is one of the largest players in the global hemp industry). The CMK Group thus gained the exclusive right to register and introduce medical marijuana-based products offered by the German concern to the Polish market.

Read More
medicane news

MediCane Health Inc. Announce First Patient Enrolled in a Phase IIa Clinical Trial of MediCane’s Balanced T3:C3 Oral Medical Cannabis Oil for Symptom Relief of Behavioral and Psychological Symptoms of Dementia (BPSD)

KFAR SAVA, Israel, October 20, 2022–(BUSINESS WIRE)–MediCane Health Inc. (along with its subsidiaries together referred to as “MediCane”) today announced the recruitment of the first patient for its clinical study designed to achieve relief of agitation and disruptive behaviors in subjects with probable Alzheimer’s disease (AD) who do not respond or only partially respond to treatment with antipsychotic medications.

Read More
Sanity Group

Portugal, South Africa and Canada: Sanity Group strengthens and diversifies its global partner network

Berlin-based Sanity Group has signed new, exclusive supply agreements for medical cannabis with partners from Portugal, South Africa and Canada, securing further exclusive rights to around 20 high-THC cannabis flos from selected cultivars with a minimum volume of three tons per year for the brands Vayamed and AVAAY Medical. Deliveries are already scheduled to start at the end of the third quarter and beginning of the fourth quarter of 2022. In addition, further important strategic partnerships have been signed.

Read More

Dr. Reddy’s Laboratories and MediCane Health announce the launch of medical cannabis products in Germany

As part of a collaboration between Dr. Reddy’s and MediCane that started in 2021, MediCane will supply the medical cannabis products to Dr. Reddy’s from its EU-GMP-certified facilities in Portugal along with providing logistical and regulatory support. As the exclusive distributor of the products in Germany, Dr. Reddy’s will provide access to MediCane’s medical cannabis products supported by a specialized field force that can provide education on the use of the products and guidance on the health insurance reimbursement process to healthcare professionals. The launch marks MediCane’s entry into the pharmaceutical sector of a major European market.

Read More

MediCane Portugal Awarded EU-GMP Certification

MediCane Health Inc. announces that its Portuguese subsidiary MHI Cultivo Medicinal has received European Union Good Manufacturing Practices (EU-GMP) certification from Infarmed, the Portuguese National Authority for Medicines and Health products, to produce cannabis for medical and research purposes. MediCane .is the third cannabis company in Portugal to be granted EU-GMP certification. The certification provides MediCane with the ability to manufacture and export cannabis-based preparations, extracts, and substances for medical.and research use in permitted jurisdictions throughout the European Union, making it well-positioned to be a cannabis export hub to Europe.

Read More
Skip to content